Last updated: September 8, 2026
Elafibranor, marketed in the United States as Iqirvo by Ipsen, received FDA accelerated approval on June 10, 2024, for primary biliary cholangitis (PBC) in adults with an inadequate response to ursodeoxycholic acid or intolerance to it. The drug is positioned as a second-line treatment for a rare autoimmune liver disease, with commercial value driven by orphan-drug pricing, long-term treatment duration, and limited approved alternatives.
Ipsen controls commercialization under its licensing agreement with Genfit. Genfit’s financial trajectory depends on upfront consideration, development and regulatory milestones, sales-based royalties, and the performance of its broader clinical portfolio. Elafibranor failed in nonalcoholic steatohepatitis, now generally called metabolic dysfunction-associated steatohepatitis, but its PBC approval restored value to the asset.
What is elafibranor and how does Iqirvo work?
Elafibranor is an oral, once-daily agonist of the peroxisome proliferator-activated receptors alpha and delta, or PPAR-alpha/delta. The drug is intended to improve cholestatic biomarkers and reduce disease activity in PBC.
The FDA-approved dose is 80 mg orally once daily. Iqirvo can be used with ursodeoxycholic acid, commonly called UDCA, or as monotherapy in patients who cannot tolerate UDCA. The accelerated approval was based primarily on biochemical response, including reductions in alkaline phosphatase, rather than definitive evidence of reduced liver transplantation or mortality risk. A post-approval confirmatory trial is required to verify clinical benefit. (FDA, 2024a)
PBC is a chronic autoimmune disease that predominantly affects women and can progress to cirrhosis, liver failure, and transplant. UDCA remains the standard first-line therapy. Patients with inadequate biochemical response or intolerance require additional treatment.
Key product facts
| Attribute |
Elafibranor / Iqirvo |
| Active ingredient |
Elafibranor |
| Developer |
Genfit |
| Commercial partner |
Ipsen |
| FDA approval |
June 10, 2024 |
| Indication |
PBC with inadequate UDCA response or UDCA intolerance |
| Dose |
80 mg once daily |
| FDA pathway |
Accelerated approval |
| Drug class |
PPAR-alpha/delta agonist |
| Treatment type |
Chronic oral therapy |
| Regulatory exclusivity |
Orphan-drug exclusivity expected to run through June 2031, subject to applicable statutory conditions |
| Main commercial market |
United States initially, followed by Europe and other territories |
What is the commercial opportunity for elafibranor in PBC?
The commercial opportunity is smaller than the market for common metabolic or cardiovascular drugs but has a favorable pricing structure. PBC is a rare disease with a concentrated specialist prescriber base, chronic treatment, and a substantial population inadequately served by UDCA.
The addressable population includes:
- Patients receiving UDCA who fail to achieve adequate biochemical control.
- Patients unable to tolerate UDCA.
- Patients who discontinue or cannot access other second-line therapies.
- Patients with progressive disease who require long-term risk reduction.
Commercial penetration will depend on several factors:
- The size of the diagnosed PBC population.
- The percentage with inadequate UDCA response.
- Payer acceptance of accelerated-approval evidence.
- Physician confidence in long-term clinical benefit.
- Competition from other PPAR agonists.
- Reimbursement restrictions and prior authorization.
- The confirmatory trial’s ability to validate clinical benefit.
The United States is the most important initial market because of high specialty-drug pricing, centralized hepatology prescribing, and the absence of a generic substitute. Europe offers a large patient base but generally imposes stronger health-technology-assessment and cost-effectiveness controls.
How does elafibranor compare with competing PBC drugs?
Elafibranor entered a market historically dominated by UDCA and obeticholic acid. Its competitive position depends on tolerability, label restrictions, treatment sequencing, and evidence of clinical benefit.
| Drug |
Mechanism |
Position in PBC |
Commercial considerations |
| Ursodeoxycholic acid |
Hydrophilic bile acid |
First-line standard |
Low-cost and widely available |
| Obeticholic acid |
FXR agonist |
Second-line treatment historically |
Safety, access, and regulatory issues weakened its position |
| Elafibranor |
PPAR-alpha/delta agonist |
Second-line treatment |
Oral dosing, orphan positioning, accelerated approval |
| Seladelpar |
PPAR-delta agonist |
Emerging competitor |
Potentially direct class competition after regulatory review |
| Fibrates |
PPAR activity, jurisdiction-dependent |
Off-label or regional use |
Generic pricing and variable regulatory status |
Elafibranor’s most direct commercial competitors are other PPAR-directed treatments, particularly seladelpar. The drugs may compete for the same UDCA-inadequate population, although treatment decisions will depend on safety labeling, liver disease severity, formulary placement, and physician familiarity.
What are the FDA exclusivity and patent timelines for Iqirvo?
The most important U.S. regulatory protection is orphan-drug exclusivity. Iqirvo’s PBC approval is expected to receive seven years of market exclusivity from the approval date, placing the principal statutory period through approximately June 10, 2031. Orphan exclusivity prevents FDA approval of the same drug for the same indication during the protected period, subject to statutory exceptions.
Orphan exclusivity does not block every possible competing product. It does not prevent:
- Approval of a different active ingredient.
- Competition from another PPAR agonist.
- Certain products that demonstrate clinical superiority.
- Patent challenges or launches after relevant patent expiration.
- Off-label use of another approved product.
Elafibranor may also benefit from patents covering the active compound, pharmaceutical compositions, methods of treatment, and manufacturing processes. Patent life must be assessed by patent family rather than by a single headline expiration date. Relevant variables include patent-term adjustment, patent-term extension, terminal disclaimers, continuation practice, and Orange Book listing.
What is the Orange Book status of Iqirvo?
Iqirvo’s patent and exclusivity position should be evaluated through the FDA Orange Book and related patent records. The commercial risk analysis requires confirmation of:
- Listed U.S. patents.
- Patent expiration dates.
- Pediatric exclusivity, if granted.
- Use codes for method-of-use patents.
- Whether patents cover the approved dosage form or only specific indications.
- Any delisting or certification disputes.
The regulatory exclusivity period is more clearly established than the full practical patent runway. A valuation that assumes generic entry immediately after orphan exclusivity would be incomplete if enforceable composition or formulation patents extend beyond 2031.
When does elafibranor lose exclusivity?
The principal orphan-drug exclusivity period is expected to end in June 2031. Patent protection could extend the effective market barrier beyond that date, but the exact generic-entry date depends on the Orange Book record and litigation outcomes.
A likely U.S. exclusivity sequence is:
| Period |
Protection or event |
| June 2024 |
FDA accelerated approval |
| 2024-2026 |
Initial market uptake, payer restrictions, confirmatory-trial execution |
| 2026-2029 |
Potential label expansion or benefit-risk reassessment |
| 2031 |
Expected end of seven-year orphan exclusivity |
| After patent expiry |
Potential Abbreviated New Drug Application competition |
| Post-entry |
Price erosion and share migration to generic elafibranor |
The most material near-term risk is not generic entry. It is failure of the confirmatory trial, a restrictive label, weak reimbursement, or displacement by a better-positioned PBC therapy.
What is the Paragraph IV risk for elafibranor?
A Paragraph IV challenge is unlikely to be the primary near-term threat because the product received approval in 2024 and the potential commercial market is relatively specialized. Generic manufacturers generally wait until the market opportunity supports the cost of development, formulation, regulatory filing, and patent litigation.
Potential Paragraph IV activity would focus on:
- Composition-of-matter patents.
- Formulation patents.
- Polymorph or salt patents.
- Method-of-use patents.
- Any patents covering the 80 mg tablet.
A first-filer could receive 180 days of generic exclusivity if statutory requirements are met. However, the value of that opportunity would depend on the remaining patent term, the number of competing filers, and whether the generic applicant can obtain approval for a non-protected indication.
Does elafibranor face biosimilar risk?
No. Elafibranor is a small-molecule drug, not a biologic. It faces generic-drug risk rather than biosimilar risk.
Generic competition can be more disruptive than biosimilar competition because an approved small-molecule generic may be automatically substitutable at the pharmacy level, depending on state law and product rating. Once relevant patents and exclusivity expire, price erosion could be rapid.
What financial deal did Genfit sign with Ipsen?
Genfit granted Ipsen rights to develop and commercialize elafibranor under a 2021 licensing agreement. Publicly disclosed economics included:
- An upfront payment of approximately €120 million.
- Potential development, regulatory, and commercial milestones of up to approximately €480 million.
- Tiered royalties on net sales.
Ipsen assumed substantial responsibility for late-stage development, regulatory submissions, manufacturing, and commercialization in the licensed territories. Genfit retained economic exposure through milestones and royalties rather than bearing the full cost of global commercialization. (Ipsen, 2021)
The structure reduced Genfit’s development financing burden while transferring operating control to a company with a broader specialty-commercial infrastructure. For Ipsen, the deal offered access to an advanced rare-disease liver asset at a time when PBC had limited treatment options.
How did elafibranor’s financial trajectory change after the NASH failure?
Elafibranor’s financial history has two distinct phases.
NASH development failure
Genfit originally developed elafibranor as a treatment for nonalcoholic steatohepatitis. In 2020, the company discontinued the Phase 3 RESOLVE-IT trial after an interim analysis determined that the study was unlikely to meet its primary endpoint. The decision sharply reduced the asset’s valuation and forced Genfit to refocus on other indications. (Genfit, 2020)
The NASH failure had three financial effects:
- It eliminated the largest potential market opportunity.
- It weakened the probability-weighted value of the molecule.
- It increased the importance of licensing and partnership income.
PBC recovery
PBC offered a smaller market but a more achievable regulatory path. Positive Phase 3 ELATIVE data restored development value and supported the Ipsen partnership. The FDA approval converted elafibranor from a development-stage asset into a commercial royalty stream.
Genfit’s future economics depend on four variables:
- Ipsen’s launch speed and market access execution.
- Achievement of commercial milestones.
- Royalty rates and net-sales growth.
- Durability of the PBC franchise against competing PPAR products.
Genfit’s cash position and income statement should not be interpreted as equivalent to product sales. Upfront payments and milestones can create lumpy revenue, while royalties develop gradually as prescriptions increase. Ipsen captures product revenue, while Genfit records partnership-related economics under the licensing arrangement.
What revenue trajectory is realistic for Iqirvo?
Iqirvo’s revenue trajectory is likely to follow a specialty-orphan launch curve:
| Phase |
Commercial pattern |
Main driver |
| Launch year |
Limited initial revenue |
Formulary access, specialist education, diagnosis |
| Years 2-3 |
Accelerating sales |
Repeat prescriptions and payer normalization |
| Years 4-6 |
Peak share-building period |
Expansion among UDCA-inadequate patients |
| Years 7 onward |
Competitive pressure increases |
New entrants, label outcomes, patent timing |
| Post-generic entry |
Potential sharp decline |
Substitution and price erosion |
Peak sales depend on the size of the treated PBC population and price per patient. The product does not need mass-market penetration to generate material revenue because PBC is chronic and specialty-drug pricing is high. It does, however, require durable reimbursement and evidence that clinicians accept biochemical response as a sufficient basis for continued treatment.
The main limitation is the accelerated-approval framework. If confirmatory evidence does not establish clinical benefit, FDA could impose label changes or pursue withdrawal. That creates a higher commercial discount rate than for a product approved on definitive outcomes data.
What manufacturing and intellectual-property barriers protect elafibranor?
The active ingredient is a chemically defined small molecule, so manufacturing barriers are lower than for biologics. Generic developers would not face cell-line development or complex biosimilar comparability requirements.
Potential barriers include:
- Control of the approved solid-state form.
- Reproducible tablet manufacturing.
- Impurity specifications.
- Stability and dissolution requirements.
- Regulatory validation of active pharmaceutical ingredient production.
- Patent claims covering formulations or manufacturing steps.
These barriers can delay competition but are unlikely to create the same long-term protection associated with biologic manufacturing platforms. The strongest protection is likely to come from regulatory exclusivity and composition-of-matter patents rather than manufacturing complexity.
What litigation and settlement risks affect elafibranor?
No major public Paragraph IV litigation was established at the time of FDA approval. The principal litigation risks are prospective:
- ANDA patent litigation after generic filings.
- Disputes over Orange Book listings.
- Challenges to method-of-use patents.
- Licensing disputes between Genfit and Ipsen.
- Commercial disputes involving milestone calculations or royalty reporting.
- Product-liability litigation based on adverse events or pregnancy exposure.
A settlement with a generic applicant could establish an agreed launch date before patent expiry. The value of such a settlement would depend on whether the generic receives a licensed entry date, a limited indication, or a license tied to patent validity.
Key Takeaways
- Elafibranor became a commercial product with FDA’s June 2024 accelerated approval of Iqirvo for PBC.
- Ipsen controls commercialization, while Genfit retains milestone and royalty economics.
- The principal regulatory exclusivity period is expected to run through June 2031.
- Elafibranor has no biosimilar risk because it is a small molecule; future competition will come from generics and competing PBC drugs.
- The product’s value is concentrated in a chronic, specialty market with limited approved therapies.
- The largest near-term risk is confirmatory-trial failure or weak payer adoption, not immediate generic entry.
- Genfit’s financial upside is more likely to appear through milestones and royalties than through direct product revenue.
- Patent value must be assessed through the complete Orange Book and patent-family record, including composition, formulation, method-of-use, and manufacturing claims.
- Elafibranor’s NASH failure limits its historical valuation, while the PBC approval provides a narrower but commercially credible recovery path.
FAQs about elafibranor market and financial outlook
Is elafibranor approved for NASH?
No. Elafibranor was discontinued in the Phase 3 RESOLVE-IT NASH trial after an interim analysis showed that the study was unlikely to meet its primary endpoint. Its approved indication is PBC.
Who owns Iqirvo?
Ipsen commercializes Iqirvo under a licensing agreement with Genfit. Genfit is the original developer and retains milestone and royalty economics under the agreement.
Is Iqirvo a first-line PBC treatment?
No. Iqirvo is used in patients with inadequate response to UDCA or intolerance to UDCA. It is positioned as a second-line treatment.
How long will Iqirvo have orphan-drug exclusivity?
The expected seven-year orphan-drug exclusivity period runs from the June 10, 2024, FDA approval and is expected to end in June 2031, subject to statutory conditions.
Can a generic version of elafibranor be launched before 2031?
A generic applicant could file an ANDA and challenge listed patents, but commercial launch would depend on patent litigation, settlements, regulatory exclusivity, and any applicable court injunction. Orphan exclusivity and patent protection create separate barriers.
References
-
Food and Drug Administration. (2024a, June 10). FDA approves first treatment for primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid. U.S. Department of Health and Human Services.
-
Genfit. (2020, May 11). Genfit announces results of the interim analysis of the RESOLVE-IT Phase 3 trial. Genfit S.A.
-
Ipsen. (2021, December 13). Ipsen and Genfit enter into an exclusive licensing agreement for elafibranor in primary biliary cholangitis. Ipsen.
-
Genfit. (2024). Annual financial report and corporate disclosures. Genfit S.A.
-
Food and Drug Administration. (2024b). Iqirvo prescribing information. U.S. Department of Health and Human Services.
